José Antonio Monge-Argilés

Dr. José Antonio Monge-Argilés

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2019 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
MGMARÍA SALUD GARCÍA-AYLLÓN
MARÍA SALUD GARCÍA-AYLLÓN
JMJosé Antonio Monge-Argilés
José Antonio Monge-Argilés
VMVictoria Monge‐García
Victoria Monge‐García
FNFrancisco Navarrete
Francisco Navarrete
MCMaria‐Angeles Cortés‐Gómez
Maria‐Angeles Cortés‐Gómez
JVJavier Sáez Valero
Javier Sáez Valero

12 March 2011 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
JMJosé Antonio Monge-Argilés
José Antonio Monge-Argilés
CMC. Muñoz-Ruiz
C. Muñoz-Ruiz
APA. Pampliega-Pérez
A. Pampliega-Pérez
MGM. J. Gómez-López
M. J. Gómez-López
JSJ. Sánchez-Payá
J. Sánchez-Payá
CLC. Leiva-Santana
C. Leiva-Santana

10 September 2021 in Medicina
Verified
Journal Article
Open access
PDF file
VMVictoria Monge-García
Victoria Monge-García
MGMARÍA SALUD GARCÍA-AYLLÓN
MARÍA SALUD GARCÍA-AYLLÓN
JVJavier Sáez Valero
Javier Sáez Valero
JSJosé Sánchez-Payá
José Sánchez-Payá
FRANCISCO NAVARRETEFRANCISCO NAVARRETE
FRANCISCO NAVARRETE
JMJosé Antonio Monge-Argilés
José Antonio Monge-Argilés
Background: Alzheimer’s disease (AD) is characterized by the presence of β-amyloid plaques and neurofibrillary tangles, while Lewy body dementia (LBD) is characterized by α-synuclein (α-syn) inclusions. Some authors examine α-syn protein in the neurodegeneration process of AD and propose to consider cerebrospinal fluid (CSF) α-syn as a possible additional biomarker to the so-called “core” of AD. Objective: To determine whether there is a correlation between α-syn levels and “core” AD biomarkers in patients with mild cognitive impairment (MCI). Materials and methods: In total, 81 patients in the early stages of MCI were selected from the outpatient dementia consultation in Alicante General Hospital. Using a cross-sectional case–control design, patients were analyzed in four groups: stable MCI (MCIs; n = 25), MCI due to AD (MCI-AD; n = 32), MCI due to LBD (MCI-LBD; n = 24) and a control group of patients with acute or chronic headache (Ctrl; n = 18). Correlation between CSF protein levels in the different groups was assessed by the Rho Spearman test. Results: We found positive correlations between T-tau protein and α-syn (ρ = 0.418; p value < 0.05) and p-tau181p and α-syn (ρ = 0.571; p value < 0.05) exclusively in the MCI-AD group. Conclusion: The correlation found between α-syn and tau proteins in the first stages of AD support the involvement of α-syn in the pathogenesis of AD. This result may have clinical and diagnostic implications, as well as help to apply the new concept of “precision medicine” in patients with MCI.

4 March 2010
Verified
Journal Article
Closed access
JMJosé Antonio Monge-Argilés
José Antonio Monge-Argilés
JSJosé Sánchez-Payá
José Sánchez-Payá
CMCarlos Muñoz-Ruiz
Carlos Muñoz-Ruiz
APAna Pampliega-Pérez
Ana Pampliega-Pérez
JMJavier Montoya-Gutiérrez
Javier Montoya-Gutiérrez
CLCarlos Leiva-Santana
Carlos Leiva-Santana

22 March 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JMJosé Antonio Monge-Argilés
José Antonio Monge-Argilés
RGR. Gasparini-Berenguer
R. Gasparini-Berenguer
MGM. Gutierrez-Agulló
M. Gutierrez-Agulló
CMC. Muñoz-Ruiz
C. Muñoz-Ruiz
JSJ. Sánchez-Payá
J. Sánchez-Payá
CLC. Leiva-Santana
C. Leiva-Santana
Objectives. To evaluate the association between apolipoprotein E (APOE) genotype and cerebrospinal fluid (CSF) levels of Alzheimers disease (AD) biomarkers and to study the influence of APOE genotype on the development of AD in a Spanish population. Material and Methods. The study comprised 29 amnestic mild cognitive impairment (MCI) patients and 27 control subjects. Using ELISA methodology, CSF biomarkers and tau/Aβ ratios were obtained. ANOVA and adjusted odds ratios were calculated. Results. We observed the effect of APOE genotype and age on CSF AD variables. The progression to AD was more clearly influenced by CSF AD variables than by age or APOE status. Conclusions. APOE status influences CSF AD variables. However, the presence of APOE ε4 does not appear to be a deterministic factor for the development of AD, because CSF variables have a greater influence on progression to the disease. These results confirm previous observations and, to our knowledge, are the first published in a Spanish population. Objectives. To evaluate the association between apolipoprotein E (APOE) genotype and cerebrospinal fluid (CSF) levels of Alzheimers disease (AD) biomarkers and to study the influence of APOE genotype on the development of AD in a Spanish population. Material and Methods. The study comprised 29 amnestic mild cognitive impairment (MCI) patients and 27 control subjects. Using ELISA methodology, CSF biomarkers and tau/Aβ ratios were obtained. ANOVA and adjusted odds ratios were calculated. Results. We observed the effect of APOE genotype and age on CSF AD variables. The progression to AD was more clearly influenced by CSF AD variables than by age or APOE status. Conclusions. APOE status influences CSF AD variables. However, the presence of APOE ε4 does not appear to be a deterministic factor for the development of AD, because CSF variables have a greater influence on progression to the disease. These results confirm previous observations and, to our knowledge, are the first published in a Spanish population.

1 September 2014 in Neurología
Verified
Journal Article
Closed access
JMJosé Antonio Monge-Argilés
José Antonio Monge-Argilés
MCM.A. Blanco Cantó
M.A. Blanco Cantó
LFL. Flors
L. Flors
CRC. Muñoz Ruiz
C. Muñoz Ruiz
JPJ. Sánchez Payá
J. Sánchez Payá
CSC. Leiva Santana
C. Leiva Santana